AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Wilk Technologies Ltd.

Investor Presentation Jan 17, 2024

7112_rns_2024-01-17_f2abff3d-d767-4ca8-a59e-289980103cf9.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

The next evolutionary step is on us

Forward Looking Statement

This presentation was prepared by Wilk Technologies Ltd. (the "Company") and is given to you only for the provision of concise information for the sake of convenience and may not be copied or distributed to any other person. The data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing.

This presentation does not purport to be comprehensive or to contain any and all information which might be relevant in connection with the making of a decision on an investment in securities of the Company. No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. In particular, no representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Company. To obtain a full picture of the activities of the Company and the risks entailed thereby, see the full immediate and periodic reports filed in connection with the Company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd., including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance. For the avoidance of doubt, it is clarified that the Company does not undertake to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation. This presentation is not an offer or invitation to buy or subscribe to any securities. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or an opinion, nor a substitute for the discretion of a potential investor.

Developing the Future:

Cow milk without cows

Human Breastmilk without mothers

In a lab setting

We Focus on human Milk fat

Compositional Dynamics of the Milk Fat Globule and Its Role in Infant Development

Hanna Lee, Emily Padhi, Yu Hasegawa, Jules Larke, Mariana Parenti, Aidong Wang, Olle Hernell, Bo Lonnerdal, Carolyn Slupsky

Clinical benefits of Milk fat globule membranes for infants and children

Olle Hernell, MD, PhD, Niklas Timby, MD PhD, Magnus Domellof, MD, and Bo Lonnerdal, Phd

The Journal of pediatrics 173, S60-S65, 2016

Disruptive Products

Cultured human milk Ingredients for

Infant Nutrition Dairy substitute ingredients

the baby formula industry Ingredients that are bovine-like for the dairy alternative ingredients industry.

Medical Nutrition

Infant based nutrition to support brain and nerve disease patients

We care about the world, and babies

Global Dairy Alternatives Market1,2

\$57Bn

Global Infant Formula Market1,2

Source: Mordor Intelligence, Euromonitor as of August 30, 2021. | (1) Estimated 2024 global TAM; (2) As per Euromonitor; (3) As per Mordor Intelligence.

Go-to-market Strategy

is officially an Exclusive Patent Holder

of methods & technologies for cultured animal milk and breastmilk production

Sales and Marketing Strategy

Focus on Human and Cow Milk Ingredients

Commercialization through collaborators and third parties

Development and clinical trials for medical foods

We are currently working on scaling-up internally and on media development. We aim to collaborate with strategic partners to sell our cultured fat and integrate our ingredients into their products.

Competitive landscape

Company Website State/Region Main Goal of R&D
Gavan https://www.gavan.bio/fatrix Israel Plant based vegan
substitutes of fats
Perfect Day https://perfectday.com/ India and
Berkely Ca
Production of ingredients
for dairy industry
fermentation
Biomilq https://www.biomilq.com/ Canada mammary biotechnology
to make human milk
outside the body
Turtle Tree https://www.turtletree.com/ Singapore precision fermentation, LF+
Opalia
Foods
https://www.opaliafoods.com/ Canada Cell based dairy foods
New Culture https://www.newculture.com/ Cheese by Casein
fermentation

About Us

10+ Years of proprietary research

13 Full -time employees

6 Patents granted

100% Farm -free

\$14 m Capital raised to date

.

100

with cell

world

milk lipids

R&D scientists

We replicate the milk

in laboratory settings.

.

We are supported by

producing process to create

We have developed the first

yogurt in the world made

% real milk components

-cultured bovine

-class team of talented

-

a

A Strategic partnership with the Central Bottling Company & Danone

.

2020 Founded in Israel

5 SDGs compliance

2 Human clinical trials

100% R E A L MILK

202 7 Expected commercialization

We are actively raising and seeking strategic partners.

Join us in growing, for a better life.

The Team

Avital Beck, PhD

CEO

Dr. Avital beck is a serial entrepreneur that holds a PhD in molecular cell biology from the Weizmann institute. She has an MBA and 10+ years' experience in managerial positions. She is an expert in molecular genetics and microbiology.

Prof. Nurit Argov-Argaman

CSO

15+ years of specialization in the study of metabolic control in milk compositions. Senior Lecturer at the Hebrew University of Jerusalem. Postdoctoral Fellowship in Food Science and Technology.

Zohar Barbash, PhD

CTO

Dr. Barbash holds PhD in Molecular genetics from Tel Aviv university and a postdoc at the National cancer institute, Bethesda MD, US, in molecular and cellular biology. Zohar has extensive experience as an executive, leading complex projects in various areas of research and product development.

Moran Attar, CPA

CFO

15 years of experience as a financial advisor and accountant- in the pharma, retail, high-tech and foodtech industries; including TASE, Nasdaq and LSE listed companies. Hold an M.A. in Accounting.

ADVISORS

Yael Ravhon

Advisor Former founder and CEO of Abbott Israel. 20+ years of experience in the field of pharma, medical nutrition and baby food.

Prof. Bruce German

Advisor

Top global KOL in the scientific field of milk and breast milk. Respected advisor to various and globally leading dairy companies.

Prof. Ronit Lubetzky

Advisor

Director of the Pediatrics Department at Tel Aviv Medical Center. Awarded scientist with specific research area on human milk composition in various maternal and neonatal settings.

Design: Vered Nevo Agency www.wilkismilk.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.